logo

For the Inventor, By the Inventor

North York, Canada

Connaught Laboratories Limited

USPTO Granted Patents = 145

% Expired Patents = 2.1



Trademarks = 4

Forward Citations = 2,218

Loading Chart...
Loading Chart...

116 inventors (with patents filed for the assignee):

goldMedal Michel Henri Klein (96 out of 164 patents)

silverMedal Pele Chong (44 out of 63 patents)

bronzeMedal Sheena M Loosmore (41 out of 68 patents)

4.  Yan-Ping Yang (27 out of 43 patents)

5.  Raymond P Oomen (18 out of 50 patents)

6.  Mary E Ewasyshyn (13 out of 27 patents)

7.  Benjamin Rovinski (12 out of 31 patents)

8.  Robert S Becker (12 out of 15 patents)

9.  Gavin Ross Zealey (12 out of 13 patents)

10.  Robin E Harkness (11 out of 22 patents)

11.  Anthony Bernard Schryvers (11 out of 30 patents)

12.  Andrew D Murdin (10 out of 44 patents)

13.  Run-Pan Du (10 out of 19 patents)

14.  Stephen A Cockle (10 out of 11 patents)

15.  Charles D Sia (10 out of 10 patents)


Core Competencies:
Immunological Compositions
Vaccine Development
Transferrin Receptor
Chimeric Proteins
Viral Envelope Proteins
Synthetic Peptides
Immune Response
Respiratory Syncytial Virus
Pertussis Toxin
Nucleic Acids
Antigen Detection
Biodegradable Microparticles

145 patents:

1. 7235243 - Immunological combination compositions and methods (2007-06-26),
2. 7118749 - Transferrin receptor genes (2006-10-10),
3. 6984385 - Immunological combination compositions and methods (2006-01-10),
4. 6538118 - Expression of lipoproteins (2003-03-25),
5. 6444211 - Purification of a pertussis outer membrane protein (2002-09-03),
6. 6403102 - Chlamydia antigens and corresponding DNA fragments and uses thereof (2002-06-11),
7. 6403101 - Chlamydia antigens and corresponding DNA fragments and uses thereof (2002-06-11),
8. 6379675 - Immunological combination compositions and methods (2002-04-30),
9. 6306637 - Production of virus and purification of viral envelope proteins for vaccine use (2001-10-23),
10. 6291157 - Antigenically-marked non-infectious retrovirus-like particles (2001-09-18),
11. 6262016 - Transferrin receptor genes (2001-07-17),
12. 6251405 - Immunological combination compositions and methods (2001-06-26),
13. 6245549 - Production of virus and purification of viral envelope proteins for vaccine use (2001-06-12),
14. 6235523 - Vectors for DNA immunization against cervical cancer (2001-05-22),
15. 6228423 - Biodegradable targetable microparticle delivery system (2001-05-08),
Company Overview
Connaught Laboratories Limited, based in North York, Canada, specializes in the development and manufacturing of immunological vaccines. The company focuses on innovative technologies related to immunological compositions, including chimeric proteins and synthetic peptides. Its research encompasses critical areas such as the transferrin receptor and viral envelope proteins, aiming to enhance immune responses against various pathogens, including the respiratory syncytial virus. Connaught Laboratories is dedicated to advancing vaccine solutions that address global health challenges.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

145 Patents

#1 in North York

#84 in Canada

#5,627 in the World

North York, CA
North York, Canada

Connaught Laboratories Limited

Forward Citations = 2,218

116 inventors:

goldMedal Michel Henri Klein (96 out of 164 patents)

silverMedal Pele Chong (44 out of 63 patents)

bronzeMedal Sheena M Loosmore (41 out of 68 patents)

4.  Yan-Ping Yang (27 out of 43 patents)

5.  Raymond P Oomen (18 out of 50 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Connaught Laboratories Limited. Retrieved from https://idiyas.com/company/connaught-laboratories

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…